Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did Maze Therapeutics (MAZE) announce in its latest 8-K filing?

How many Maze Therapeutics (MAZE) shares were represented at the 2026 annual meeting?

Who was elected to the Maze Therapeutics (MAZE) board at the 2026 annual meeting?

What were the vote results for Maze Therapeutics’ (MAZE) auditor ratification in 2026?

Did Maze Therapeutics (MAZE) achieve a quorum at its 2026 annual stockholder meeting?

What is the term length for directors elected at Maze Therapeutics’ (MAZE) 2026 meeting?

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Maze Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting. A total of 44,660,029 shares of common stock, representing approximately 89.75% of the shares entitled to vote, were present or represented by proxy, establishing a quorum.

Stockholders elected Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as directors to serve until the 2029 annual meeting, with 35,792,536 and 34,056,425 votes for, respectively, and broker non-votes recorded on both. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,557,778 votes for, 728 against, and 101,523 abstentions.

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Shares represented at meeting: 44,660,029 shares Voting participation: 89.75% of shares Votes for Jason Coloma: 35,792,536 votes +4 more

7 metrics

Shares represented at meeting 44,660,029 shares Common stock present or by proxy at 2026 annual meeting

Voting participation 89.75% of shares Percentage of outstanding shares entitled to vote represented at meeting

Votes for Jason Coloma 35,792,536 votes For election as director at 2026 annual meeting

Votes for Neil Kumar 34,056,425 votes For election as director at 2026 annual meeting

Auditor ratification votes for 44,557,778 votes For ratifying Ernst & Young LLP for year ending December 31, 2026

Auditor ratification votes against 728 votes Against ratifying Ernst & Young LLP for 2026

Auditor ratification abstentions 101,523 votes Abstentions on ratifying Ernst & Young LLP for 2026

quorum, broker non-votes, independent registered public accounting firm, emerging growth company, +1 more

5 terms

quorum financial

"were present virtually or represented by proxy, which constituted a quorum for the transaction of business"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

broker non-votes financial

"Jason Coloma, Ph.D. ... Votes Withheld ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

annual meeting of stockholders financial

"held its 2026 annual meeting of stockholders (the “Annual Meeting”)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/10/2026 - 04:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2026

Maze Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-42490	82-2635018
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

171 Oyster Point Blvd., Suite 300
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 850-5070

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock - par value $0.001 per share

MAZE

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 8, 2026, Maze Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). 44,660,029 shares of common stock, representing approximately 89.75% of the total outstanding shares entitled to vote at the Annual Meeting, were present virtually or represented by proxy, which constituted a quorum for the transaction of business. The Company’s stockholders who were present virtually or represented by proxy voted on two proposals at the Annual Meeting, each of which is described below and more fully in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”).

At the Annual Meeting, the Company’s stockholders voted on the following proposals:

To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company’s 2029 annual meeting of stockholders and until such director’s successor has been duly elected and qualified, or until such director’s earlier death, resignation, disqualification, retirement, or removal.

2.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

The final voting results for each of these proposals are as follows:

Proposal 1: Election of Directors.


Nominee	Votes For		Votes Withheld		Broker Non-Votes
Jason Coloma, Ph.D.		35,792,536		5,926,467		2,941,026
Neil Kumar, Ph.D.		34,056,425		7,662,578		2,941,026

Each of the two nominees for director was elected to serve until the Company’s 2029 annual meeting of stockholders and until such director’s successor has been duly elected and qualified, or until such director’s earlier death, resignation, disqualification, retirement, or removal.

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.


Votes For	Votes Against	Abstentions	Broker Non-Votes
44,557,778	728	101,523	0

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Maze Therapeutics reported the results of its 2026 annual stockholder meeting. Stockholders elected two directors to new terms and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, with strong participation and approval levels.

At the 2026 annual meeting, 44,660,029 shares of Maze Therapeutics common stock were present or represented by proxy. This represented approximately 89.75% of the total outstanding shares entitled to vote, providing a sufficient quorum for conducting official company business and elections.

Stockholders elected Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as directors. Coloma received 35,792,536 votes for and 5,926,467 withheld, while Kumar received 34,056,425 votes for and 7,662,578 withheld, with 2,941,026 broker non-votes recorded for each nominee.

Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for 2026. The proposal received 44,557,778 votes for, 728 votes against, and 101,523 abstentions, with no broker non-votes recorded on this auditor ratification item.

Yes, Maze Therapeutics achieved a quorum at its 2026 annual meeting. A total of 44,660,029 shares, representing approximately 89.75% of the outstanding shares entitled to vote, were present virtually or by proxy, allowing the company to conduct official meeting business.

Each director elected at the 2026 annual meeting will serve until the 2029 annual meeting. They will remain in office until their successors are duly elected and qualified, or until earlier death, resignation, disqualification, retirement, or removal under applicable corporate governance rules.

Date: June 10, 2026

/s/ Courtney Phillips

Courtney Phillips

General Counsel and Corporate Secretary

3 documents